![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
Pronóstico del mercado de enfermedades cardiometabólicas de Oriente Medio y África hasta 2028: impacto de COVID-19 y análisis regional por tipo (enfermedad cardiovascular (ECV), diabetes tipo 2, hipertensión y obesidad), tratamiento (inhibidores de la ECA, diuréticos, glucófagos y otros), Dosis (tableta e inyección), vía de administración (oral e intravenosa), usuarios finales (hospitales, clínicas y entornos de atención domiciliaria) y canal de distribución (farmacia hospitalaria, farmacia minorista y farmacia en línea)
Introducción al mercado
La enfermedad cardiometabólica se caracteriza por un grupo de anomalías y síntomas que aumentan el riesgo de que las personas desarrollen enfermedades cardiovasculares. Hipertensión, obesidad, resistencia a la insulina, dislipidemia, perfil deficiente de colesterol (LDL) y tolerancia a la glucosa son algunos de los síntomas. Las personas que padecen síndrome cardiometabólico son propensas a otras enfermedades potencialmente mortales, como diabetes tipo 2, accidente cerebrovascular, enfermedad de las arterias coronarias (EAC), enfermedades cardiovasculares (CVD) y muchas otras.
Además, se espera que la creciente prevalencia de enfermedades cardiometabólicas impulse el crecimiento del mercado durante el período previsto. Sin embargo, el subdiagnóstico de las ECV en los países de ingresos bajos y medianos (PIBM) limita el crecimiento del mercado de enfermedades cardiometabólicas de Oriente Medio y África.
La pandemia ha aumentado la demanda de Dispositivos médicos que se pueden utilizar en un entorno de atención domiciliaria. La región ha observado un número creciente de pacientes ingresados en unidades de cuidados intensivos (UCI). Un número creciente de medicamentos impone múltiples desafíos diagnósticos y terapéuticos a los sistemas de salud estresados, lo que lleva a un aumento de dispositivos médicos y productos farmacéuticos. Además, ha aumentado el número de casos de enfermedades crónicas, lo que ha provocado un mayor uso de medicamentos para combatir el virus. Durante la pandemia generalizada de COVID-19, ha habido preocupación sobre el potencial de ciertos medicamentos para la presión arterial, como los inhibidores de la enzima convertidora de angiotensina (IECA) y los bloqueadores convertidores de angiotensina (BRA). El actual síndrome respiratorio agudo severo coronavirus 2 (SARS-CoV-2) utiliza los receptores de la enzima convertidora de angiotensina 2 (ACE2) unidos a la membrana para facilitar la entrada a la célula huésped. Esta pandemia mejoró la operación comercial de los diversos fabricantes de medicamentos que operan en el mercado de enfermedades cardiometabólicas en la región.
Descripción general y dinámica del mercado
Se prevé que el mercado de enfermedades cardiometabólicas de Oriente Medio y África alcance los 5.008,5 millones de dólares en 2028, desde los 4.300,9 millones de dólares de 2021; se prevé que crezca a una tasa compuesta anual del 2,2 % de 2021 a 2028. La cartera de candidatos a fármacos basados en CMD se está expandiendo para una amplia gama de aplicaciones terapéuticas, incluidas la hipertensión, la diabetes y los trastornos inflamatorios. Muchas empresas farmacéuticas, grandes y pequeñas, participan en el desarrollo de varios fármacos de molécula pequeña. Por ejemplo, AstraZeneca tiene más de 25 terapias y combinaciones de terapias en sus etapas cardiovascular, renal y metabólica (CVRM) de etapa temprana a tardía. Basados en tecnologías avanzadas, se están introduciendo varios productos para el tratamiento de las CMD. Además, la creciente inversión en investigación relacionada con las TMC está impulsando significativamente el mercado de enfermedades cardiometabólicas. Todas estas inversiones se reflejan positivamente en el crecimiento del mercado de enfermedades cardiometabólicas de Oriente Medio y África.
Segmentos de mercado clave
En términos de tipo, el segmento de enfermedades cardiovasculares representó la mayor proporción del mercado de enfermedades cardiometabólicas de Oriente Medio y África en 2020. En términos de tratamiento, el segmento de inhibidores de la ECA representó para la mayor participación del mercado de enfermedades cardiometabólicas de Medio Oriente y África en 2020. En términos de dosis, el segmento de tabletas representó la mayor participación del mercado de enfermedades cardiometabólicas de Medio Oriente y África en 2020. En términos de vía de administración, el oral El segmento representó la mayor participación del mercado de enfermedades cardiometabólicas de Medio Oriente y África en 2020. En términos de usuario final, el segmento hospitalario representó la mayor participación del mercado de enfermedades cardiometabólicas de Medio Oriente y África en 2020. Además, según el canal de distribución , el segmento de farmacia hospitalaria tuvo la mayor participación de mercado en 2020.
Principales fuentes y empresas incluidas en la lista
Algunas de las principales fuentes primarias y secundarias a las que se hace referencia para preparar este informe sobre el mercado de enfermedades cardiometabólicas en Medio Oriente y África son los sitios web de las empresas, los informes anuales, los informes financieros, documentos del gobierno nacional, y base de datos estadísticos, entre otros. Las principales empresas que figuran en el informe son Bayer AG, Novartis AG, Boehringer Ingelheim International Gmbh, Novo Nordisk A/S y AstraZeneca.
Informe de razones para comprar
- Para comprender el mercado de enfermedades cardiometabólicas de Oriente Medio y África panorama e identificar segmentos de mercado que probablemente garanticen un fuerte retorno
- Comprender el panorama del mercado en constante cambio y mantenerse a la vanguardia de la competencia
- Planificar eficientemente fusiones, adquisiciones y acuerdos de asociación en el mercado de enfermedades cardiometabólicas de Oriente Medio y África identificando segmentos con las ventas probables más prometedoras.
- Hacer negocios con conocimiento decisiones a partir de un análisis perspicaz y completo del desempeño del mercado de varios segmentos
- Para obtener un pronóstico de ingresos de mercado del mercado de enfermedades cardiometabólicas de Medio Oriente y África basado en varios segmentos para el Período 2021-2028
SEGMENTACIÓN DEL MERCADO DE ENFERMEDADES CARDIOMETABÓLICAS DE ORIENTE MEDIO Y ÁFRICA
< p>Por tipo- Enfermedad cardiovascular (ECV)
- Diabetes tipo 2
- Hipertensión
- Obesidad
< span>Por tratamiento
- Inhibidores de la ECA
- Diuréticos
- Glucophage
- Otros
Por dosis
- Tableta
- Inyección
- Oral
- Intravenosa
Por usuarios finales
- Hospital
- Clínica
- Entornos de atención domiciliaria
Por Canal de distribución
- Farmacia hospitalaria
- Farmacia minorista
- Farmacia en línea
Por país
- Oriente Medio y África
- EAU
- Arabia Saudita
- Sudáfrica
- Resto de Oriente Medio y África
Empresas mencionadas
- Bayer AG
- Novartis AG   ;
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Middle East and Africa Cardiometabolic Diseases market – By Country
2. Middle East and Africa Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East and Africa Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Middle East and Africa Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Middle East and Africa Cardiometabolic Diseases Market – Regional Analysis
6.1 Middle East and Africa Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Middle East and Africa Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Middle East and Africa Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Middle East and Africa Cardiometabolic Diseases Market – Geographic Analysis
13.1 Middle East and Africa: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 Middle East & Africa: Cardiometabolic Diseases Market - Revenue and Forecast to 2028 (US$ Million)
13.1.3 Middle East & Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 Middle East & Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 Middle East & Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 Middle East & Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 Middle East & Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.8 Middle East & Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9 Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.9.1.1 Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.10 Saudi Arabia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.11 Saudi Arabia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.12 Saudi Arabia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.13 Saudi Arabia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.14 Saudi Arabia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.15 Saudi Arabia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.15.1 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.15.1.1 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.15.1.2 UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.16 UAE: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.17 UAE: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.18 UAE: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.19 UAE: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.20 UAE: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.21 UAE: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.21.1 South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.21.1.1 South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.22 South Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.23 South Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.24 South Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.25 South Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.26 South Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.27 South Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.27.1 Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.27.1.1 Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
13.1.28 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.29 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.30 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.31 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.32 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.33 Rest of Middle East and Africa: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Middle East and Africa Cardiometabolic Diseases Market
14.1 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
15. Middle East and Africa Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Bayer AG
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Novartis AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Boehringer Ingelheim International GmbH
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Novo Nordisk A/S
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 AstraZeneca
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Middle East & Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Middle East & Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 3. Middle East & Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Middle East & Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 5. Middle East & Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 6. Middle East & Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. Saudi Arabia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. Saudi Arabia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 9. Saudi Arabia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. Saudi Arabia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 11. Saudi Arabia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 12. Saudi Arabia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. UAE Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. UAE Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. UAE Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. UAE Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 17. UAE Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 18. UAE Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 19. South Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. South Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. South Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. South Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 23. South Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 24. South Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 27. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 29. Rest of Middle East and Africa Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 30. Rest of Middle East and Africa Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 31. Organic Developments in the Cardiometabolic Diseases Market
Table 32. Inorganic Developments in the Cardiometabolic Diseases Market
Table 33. Glossary of Terms, Middle East and Africa Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Middle East and Africa Cardiometabolic Diseases Market Segmentation
Figure 2. Middle East and Africa Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Middle East and Africa Cardiometabolic Diseases Market
Figure 4. Middle East and Africa Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Middle East and Africa Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Middle East and Africa PEST Analysis
Figure 7. Middle East and Africa Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Middle East and Africa Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Middle East and Africa: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. Middle East & Africa Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Million)
Figure 35. Middle East and Africa: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. Saudi Arabia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. UAE: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. South Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Rest of Middle East and Africa: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Impact of COVID-19 Pandemic on Middle East and Africa Cardiometabolic Diseases Market
Figure 41. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East and Africa cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East and Africa cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.